(Total Views: 416)
Posted On: 10/24/2019 12:29:18 PM
Post# of 30066
Not mentioned is still the roughly 45% ownership in Todos once they uplist.
So, the curious part is Amarantus outstanding shares and Amarantus as a holding company.
"Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard. "
No debt add in royalties, milestones payments and ownership/partnership with TODOS....
Again, looking like Gerald will be getting a few yes' from this stakeholder.
Much Aloha
So, the curious part is Amarantus outstanding shares and Amarantus as a holding company.
"Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard. "
No debt add in royalties, milestones payments and ownership/partnership with TODOS....
Again, looking like Gerald will be getting a few yes' from this stakeholder.
Much Aloha
(2)
(0)
